BPG is committed to discovery and dissemination of knowledge
Case Report
Copyright: ©Author(s) 2026.
World J Gastroenterol. Dec 7, 2026; 32(45): 122564
Published online Dec 7, 2026. doi: 10.3748/wjg.122564
Figure 1
Figure 1 Temporal relationship of tirzepatide use, symptom severity, and body mass index. Symptom severity improved with tirzepatide initiation and re-initiation, worsened after dose reduction and discontinuation, and paralleled changes in drug exposure. Body mass index decreased during treatment and subsequently stabilized. BMI: Body mass index.


Write to the Help Desk